Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7587234 | 0.88 | ABCC1 (0.44) | CYP11B2KDM4EHSD17B10HTTABCC1 | |
| SCHEMBL7954850 | 0.86 | ABCC1 (0.43) | CYP11B2KDM4EHSD17B10HTTABCC1 | |
| SCHEMBL7955460 | 0.86 | ABCC1 (0.43) | KDM4EHSD17B10HTTABCC1ALDH1A1 | |
| SCHEMBL7953813 | 0.85 | ABCC1 (0.43) | CYP11B2KDM4EHSD17B10HTTABCC1 | |
| SCHEMBL2158205 | 0.85 | KDM4E (0.45) | CYP11B2KDM4EHSD17B10HTTABCC1 | |
| SCHEMBL7955035 | 0.84 | ABCC1 (0.43) | CYP11B2KDM4EHSD17B10HTTABCC1 | |
| SCHEMBL7953497 | 0.84 | CYP11B2 (0.42) | CYP11B2KDM4EHSD17B10HTTABCC1 | |
| SCHEMBL8647218 | 0.82 | ABCC1 (0.42) | CYP11B2KDM4EHSD17B10HTTABCC1 | |
| SCHEMBL7953612 | 0.82 | ABCC1 (0.41) | CYP11B2KDM4EHSD17B10HTTABCC1 | |
| SCHEMBL7946473 | 0.82 | ABCC1 (0.43) | CYP11B2KDM4EHSD17B10HTTABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6194426-B1 | CONTROLLING TUMOR NECROSIS FACTOR | RHONA-POULENC RORER S.A. (FR) | 2001-02-27 | — | — | US | claimed |
| US-20020006380-A1 | Pyrrole derivatives, their preparation and pharmaceutical compositions containing them | MIGNANI SERGE (FR) | 2002-01-17 | — | — | US | disclosed |
| EP-1086100-A1 | PYRROLE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2001-03-28 | — | — | EP | disclosed |
| US-6194426-B1 | CONTROLLING TUMOR NECROSIS FACTOR | RHONA-POULENC RORER S.A. (FR) | 2001-02-27 | — | — | US | disclosed |
| WO-1999064419-A1 | PYRROLE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006380-A1 | Pyrrole derivatives, their preparation and pharmaceutical compositions containing them | TNF, IL2, ZC3HAV1 | CYP11B2 139/4885KDM4E 710/4885HSD17B10 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.